diethyl (4-chlorobutyl)phosphonate | 86791-04-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: diethyl (4-chlorobutyl)phosphonate
• 英文别名: Diethyl(4-chlorobutyl)phosphonate；1-chloro-4-diethoxyphosphorylbutane
• CAS: 86791-04-0
• 化学式: C₈H₁₈ClO₃P
• 分子量: 228.656
• InChiKey: NFDOTROBGXYZAB-UHFFFAOYSA-N

物化性质

• 沸点：
  106 °C(Press: 0.05 Torr)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  diethyl (4-chlorobutyl)phosphonate 在 五氯化磷 作用下， 生成 1-Chlor-4-dichlorphosphinylbutan
  参考文献：
  名称：

  Helferich,B.; Curtius,U., Justus Liebigs Annalen der Chemie, 1962, vol. 655, p. 59 - 69

  摘要：

  DOI：
• 作为产物：
  描述：

  亚磷酸二乙酯 、 1,4-二氯丁烷 生成 diethyl (4-chlorobutyl)phosphonate
  参考文献：
  名称：

  Helferich,B.; Curtius,U., Justus Liebigs Annalen der Chemie, 1962, vol. 655, p. 59 - 69

  摘要：

  DOI：

文献信息

• PHOSPHATE DERIVATIVES AND USE THEREOF
  申请人：ZHU Qing

  公开号：US20210030773A1

  公开（公告）日：2021-02-04

  The present invention discloses a compound with the following formula (I), or a tautomer, mesomer, racemate, enantiomer, and diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug molecule thereof, wherein D is selected from: The invention further discloses the use of the compound in the preparation of drugs for preventing and/or treating cancers, and the use of the compound in the preparation of drugs for inhibiting cancer metastasis. The compound of the present invention can effectively inhibit the proliferation and metastasis of cancer cells by adjusting the acidity of a tumor microenvironment to achieve a better effect in clinical cancer treatment, and has broad application prospects.

  本发明公开了具有以下式（I）的化合物，或其互变异构体、共振异构体、外消旋体、对映体和非对映异构体，或其混合形式，或其药学上可接受的盐，或其前药分子，其中D从以下中选择： 该发明还公开了该化合物在制备用于预防和/或治疗癌症的药物中的用途，以及该化合物在制备用于抑制癌症转移的药物中的用途。本发明的化合物可以通过调节肿瘤微环境的酸度来有效抑制癌细胞的增殖和转移，从而在临床癌症治疗中取得更好的效果，并具有广阔的应用前景。
• Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their
  申请人：Hoechst Aktiengesellschaft

  公开号：US05728686A1

  公开（公告）日：1998-03-17

  Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals A compound of the formula ##STR1## where R.sup.1 and R.sup.3 are identical or different and at least one of the radicals R.sup.1 and R.sup.3 is a radical of the formula XI ##STR2## in which E is a covalent bond or a (C.sub.1 -C.sub.5)-alkyl, are suitable for the production of pharmaceuticals for the treatment of muscular atrophy, cachexia, muscular dystrophy, sepsis, septic shock, endotoxic shock, systemic inflammation response syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pneumonia, pulmonary sarcoidosis, reperfusion damage, scar formation, inflammation of the bowel and ulcerative colitis, as a result of infections, acquired immune deficiency syndrome, cancer, trauma and other disorders having increased protein loss, peripheral circulatory disorders, disorders having altered leucocyte adhesion, and also disorders which are accompanied by an increased or unregulated tumor necrosis factor production such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic disorders.

  烷基黄嘌呤磷酰化合物和烷基黄嘌呤磷酰亚胺氧化物及其作为药物的应用 一种具有以下公式的化合物：##STR1##，其中R.sup.1和R.sup.3相同或不同，且至少一个自由基R.sup.1和R.sup.3是具有以下公式XI的自由基：##STR2##，其中E是共价键或（C.sub.1 -C.sub.5）-烷基，适用于生产用于治疗肌萎缩、恶病质、肌营养不良、败血症、败血性休克、内毒素性休克、系统性炎症反应综合征、成人呼吸窘迫综合征、脑型疟疾、慢性肺炎、肺肉芽肿病、再灌注损伤、疤痕形成、肠炎和溃疡性结肠炎、由于感染、获得性免疫缺陷综合症、癌症、创伤以及其他具有增加蛋白质丢失的疾病、外周循环障碍、具有改变的白细胞粘附的疾病，以及那些伴随有肿瘤坏死因子产生增加或不受控制的疾病，如类风湿性关节炎、强直性脊柱炎、骨关节炎和其他关节疾病。
• ω-Alkyne-Mono- and Diphosphonates – Synthesis and Sonogashira Cross-Coupling Reaction with Aryl Halides
  作者：Lise Delain-Bioton、Didier Villemin、Paul-Alain Jaffrès

  DOI：10.1002/ejoc.200600556

  日期：2007.3

  A convergent approach to functionalise aromatic compounds with a linker terminated by a phosphonate group is reported. The starting point of this strategy is the synthesis of five new ω-alkyne-phosphonates. The linker between the phosphonate group and the alkyne part is either an alkyl or an ether chain. This strategy is based on the use of the phosphonate group as the anchoring point for the attachment

  报道了一种将芳族化合物功能化的收敛方法，该方法具有由膦酸酯基团封端的接头。该策略的起点是合成五种新的 ω-炔烃-膦酸酯。膦酸酯基团和炔部分之间的接头是烷基或醚链。该策略基于使用膦酸酯基团作为锚定点来连接
• Phosphonylation of alkyl radicals
  作者：Junyue Yin、Xinru Lin、Linxiang Chai、Cheng-Yu Wang、Lin Zhu、Chaozhong Li

  DOI：10.1016/j.chempr.2023.03.016

  日期：2023.7

  remains elusive. Herein, we report the decarboxylative radical phosphonylation with trialkyl phosphites. Thus with the co-catalysis of 4DPAIPN (1,2,3,5-tetrakis(diphenylamino)-4,6-dicyanobenzene) and Cu(OAc)2, the visible light-induced reaction of redox-active esters of aliphatic carboxylic acids with trialkyl phosphites at room temperature provides the corresponding alkylphosphonates in satisfactory

  烷基膦酸酯在药物、农用化学品和材料科学中有着广泛的应用，其合成在有机化学中至关重要。虽然亲核和亲电 C(sp 3 )-膦酰化已有充分记录，但烷基的膦酰化仍然难以捉摸。在此，我们报道了亚磷酸三烷基酯的脱羧自由基膦酰化反应。因此，在 4DPAIPN (1,2,3,5-四(二苯氨基)-4,6-二氰基苯) 和 Cu(OAc) 2的共催化下，在室温下，脂肪族羧酸的氧化还原活性酯与亚磷酸三烷基酯发生可见光诱导反应，以令人满意的产率提供相应的烷基膦酸酯。该方案具有广泛的底物范围和广泛的官能团兼容性，能够实现复杂分子的后期修饰。提出了一种涉及烷基与 P(OR) 3的铜辅助偶联，然后对所得鏻中间体进行 Arbuzov 型脱烷基化的机制。
• Aza-acyclic Nucleoside Phosphonates Containing a Second Phosphonate Group As Inhibitors of the Human, <i>Plasmodium falciparum</i> and <i>vivax</i> 6-Oxopurine Phosphoribosyltransferases and Their Prodrugs As Antimalarial Agents
  作者：Dianne T. Keough、Dana Hocková、Zlatko Janeba、Tzu-Hsuan Wang、Lieve Naesens、Michael D. Edstein、Marina Chavchich、Luke W. Guddat

  DOI：10.1021/jm501416t

  日期：2015.1.22

  Hypoxanthineguanine[xanthine] phosphoribosyltransferase (HG[X]PRT) is considered an important target for antimalarial chemotherapy as it is the only pathway for the synthesis of the purine nucleoside monophosphates required for DNA/RNA production. Thus, inhibition of this enzyme should result in cessation of replication. The aza-acyclic nucleoside phosphonates (aza-ANPs) are good inhibitors of Plasmodium falciparum HGXPRT (PfHGXPRT), with K-i values as low as 0.08 and 0.01 mu M for Plasmodium vivax HGPRT (PvHGPRT). Prodrugs of these aza-ANPs exhibit antimalarial activity against Pf lines with IC50 values (0.8-6.0 mu M) and have low cytotoxicity against human cells. Crystal structures of six of these compounds in complex with human HGPRT have been determined. These suggest that the different affinities of these aza-ANPs could be due to the flexibility of the loops surrounding the active site as well as the flexibility of the inhibitors, allowing them to adapt to fit into three binding pockets of the enzyme(s).